Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders.
The Company is initially developing VRS-317, its novel long-acting recombinant human growth hormone, for the treatment of pediatric growth hormone deficiency. VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes. The Company has recently completed a Phase 2a clinical study of VRS-317 in pediatric growth hormone deficient patients.
VRS-317 is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN, which is in-licensed from Amunix Operating, Inc. Amunix has granted Versartis a worldwide exclusive license under its patents and know-how related to the XTEN technology to develop and commercialize VRS-317 as well as another undisclosed XTEN-based product.
Versartis was founded in December 2008 and is headquartered in Menlo Park, California, USA.